Alrizomadlin

Generic Name: Alrizomadlin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₄H_₃₈Cl_₂FN_₃O_₄

CAS Number: 1818393-16-6

Unique Ingredient Identifier: 15QAU0SI9J

Background: Alrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. It is being investigated in cancers.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Phase 2

Not yet recruiting

Conditions: Mesothelioma
Malignant Mesothelioma (MM)
Early-stage Mesothelioma
Subclinical Mesothelioma
BRCA1-Associated Protein-1 (BAP1) Mutations
Early-stage BAP1-associated Malignancies

Interventions: Drug: alrizomadlin

First Posted Date: 2024-10-23

Last Posted Date: 2024-12-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT06654050

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy